Tech Center 1600 • Art Units: 1643
This examiner grants 64% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18124096 | PURIFICATION OF MULTISPECIFIC ANTIBODIES | Non-Final OA | GENENTECH, INC. |
| 18042267 | ANTIGEN BINDING PROTEINS WITH NON-CANONICAL DISULFIDE IN FAB REGION | Non-Final OA | AMGEN INC. |
| 16869793 | DOSING REGIMEN FOR ANTI-BCMA AGENTS | Non-Final OA | AMGEN INC. |
| 18186783 | ANTI-TIM3 ANTIBODIES AND METHODS OF USE | Non-Final OA | Hoffmann-La Roche Inc. |
| 18069847 | ANTI-CD3/ANTI-CD28 BISPECIFIC ANTIGEN BINDING MOLECULES | Final Rejection | Hoffmann-La Roche Inc. |
| 18051307 | PREDICTING RESPONSE TO PD-1 AXIS INHIBITORS | Final Rejection | Hoffmann-La Roche Inc. |
| 19242715 | COMPOSITIONS AND METHODS FOR TREATMENT OF THYROID EYE DISEASE | Non-Final OA | Viridian Therapeutics, Inc. |
| 16435257 | TREATMENT OF CANCER USING ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR | Final Rejection | The Trustees of the University of Pennsylvania |
| 18268840 | EFFECTORLESS FC MOLECULES | Non-Final OA | SANOFI |
| 17481578 | SERUM ALBUMIN-BINDING IMMUNOGLOBULIN VARIABLE DOMAINS | Final Rejection | Sanofi |
| 18150136 | Neoepitope vaccine and immune stimulant combinations and methods | Non-Final OA | NantCell, Inc. |
| 18018864 | MULTISPECIFIC BINDING AGENTS AND USES THEREOF | Final Rejection | EXELIXIS, INC. |
| 17929874 | TREATMENT OF ATOPIC DERMATITIS EMPLOYING ANTI-IL-13Ra1 ANTIBODY OR BINDING FRAGMENT THEREOF IN AN ALLERGIC POPULATION | Final Rejection | Aslan Pharmaceuticals PTE LTD |
| 17999477 | IMMUNOGLOBULIN Fc REGION VARIANTS COMPRISING STABILITY-ENHANCING MUTATIONS | Non-Final OA | Zymeworks BC Inc. |
| 18346975 | ANTI-HLA-DQ2.5 ANTIBODY AND ITS USE FOR THE TREATMENT OF CELIAC DISEASE | Non-Final OA | Chugai Seiyaku Kabushiki Kaisha |
| 17914432 | METHOD FOR PRODUCING MULTISPECIFIC ANTIGEN-BINDING MOLECULES | Final Rejection | Chugai Seiyaku Kabushiki Kaisha |
| 16692676 | ANTIGEN-BINDING MOLECULE HAVING REGULATED CONJUGATION BETWEEN HEAVY-CHAIN AND LIGHT-CHAIN | Final Rejection | Chugai Seiyaku Kabushiki Kaisha |
| 18320599 | TRI-SPECIFIC BINDING MOLECULES THAT SPECIFICALLY BIND TO MULTIPLE CANCER ANTIGENS | Non-Final OA | MacroGenics, Inc. |
| 18029525 | METHODS OF TREATING DERMATOMYOSITIS | Non-Final OA | Alexion Pharmaceuticals, Inc. |
| 17720954 | ANTI-CD27 AND ANTI-PD-L1 ANTIBODIES AND BISPECIFIC CONSTRUCTS | Non-Final OA | Celldex Therapeutics, Inc. |
| 18025203 | BISPECIFIC ANTIBODY AGAINST CD3 AND CD20 IN COMBINATION THERAPY FOR TREATING DIFFUSE LARGE B-CELL LYMPHOMA | Non-Final OA | GENMAB A/S |
| 17230240 | MULTISPECIFIC ANTIBODIES, MULTISPECIFIC ACTIVATABLE ANTIBODIES AND METHODS OF USING THE SAME | Non-Final OA | CytomX Therapeutics, Inc. |
| 17922230 | ANTIGEN BINDING CONSTRUCTS TARGETING HER2 AND USES THEREOF | Final Rejection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
| 17916728 | METHODS OF USE OF ANTI-TREM2 ANTIBODIES | Final Rejection | Alector LLC |
| 17786708 | POLYPEPTIDES, PROTEIN COMPLEXES AND METHOD FOR MAKING SAME | Non-Final OA | KISOJI BIOTECHNOLOGY INC. |
| 17910327 | AFFINITY MATURED AND HUMANIZED BINDING DOMAINS TARGETING ROR2 | Final Rejection | JULIUS-MAXIMILIANS-UNIVERSITÄT WÜRZBURG |
| 17762463 | BINDING MODULES COMPRISING MODIFIED EHD2 DOMAINS | Final Rejection | UNIVERSITÄT STUTTGART |
| 18250347 | RECOMBINANT T-CELL RECEPTORS THAT BIND THE NY-ESO-1 AND/OR LAGE-1A CANCER ANTIGENS | Non-Final OA | T-Cure Bioscience, Inc. |
| 17926283 | METHODS AND MEANS FOR THE PRODUCTION OF IG-LIKE MOLECULES | Final Rejection | MERUS N.V. |
| 17755196 | MEANS AND METHODS FOR TREATING SUBJECTS WITH HER2 AND HER3 POSITIVE CANCER | Final Rejection | Merus N.V. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy